204 related articles for article (PubMed ID: 28834238)
21. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
Franchini M; Mengoli C; Cruciani M; Bonfanti C; Mannucci PM
J Thromb Haemost; 2014 Sep; 12(9):1480-7. PubMed ID: 25040440
[TBL] [Abstract][Full Text] [Related]
22. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
[TBL] [Abstract][Full Text] [Related]
23. A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study.
Schnegg-Kaufmann A; Calzavarini S; Limacher A; Mean M; Righini M; Staub D; Beer JH; Frauchiger B; Osterwalder J; Kucher N; Matter CM; Husmann M; Banyai M; Aschwanden M; Mazzolai L; Hugli O; Nagler M; Daskalakis M; Rodondi N; Aujesky D; Angelillo-Scherrer A
J Thromb Haemost; 2019 Feb; 17(2):306-318. PubMed ID: 30570809
[TBL] [Abstract][Full Text] [Related]
24. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
25. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.
Leiss W; Méan M; Limacher A; Righini M; Jaeger K; Beer HJ; Osterwalder J; Frauchiger B; Matter CM; Kucher N; Angelillo-Scherrer A; Cornuz J; Banyai M; Lämmle B; Husmann M; Egloff M; Aschwanden M; Rodondi N; Aujesky D
J Gen Intern Med; 2015 Jan; 30(1):17-24. PubMed ID: 25143224
[TBL] [Abstract][Full Text] [Related]
26. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
28. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
29. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
30. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Duan L; Zhang N; Yan H; Guo Y; Hong C; Yang X; Su X; Chen R; Zhou Y; Zhong N; Liu C
Clin Chim Acta; 2016 Aug; 459():25-29. PubMed ID: 27155586
[TBL] [Abstract][Full Text] [Related]
31. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
[TBL] [Abstract][Full Text] [Related]
32. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism.
Frei AN; Stalder O; Limacher A; Méan M; Baumgartner C; Rodondi N; Aujesky D
Thromb Haemost; 2021 Nov; 121(11):1512-1522. PubMed ID: 33930905
[TBL] [Abstract][Full Text] [Related]
34. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
35. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
36. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
37. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
38. Effect of gene polymorphims on the warfarin treatment at initial stage.
Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
[TBL] [Abstract][Full Text] [Related]
39. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]